Lance Baldo, MD, is chief medical officer of Adaptive Biotechnologies.Adaptive Biotechnologies Corporation insider Baldo sold 50,000 shares of the business’s stock in a transaction dated Wednesday, May 6th.Baldo left Genentech to become chief medical officer of Adaptive Biotechnologies.Before joining Roche, Baldo was the global vice president of medical science and affairs for The Medicines Company in Parsippany, NJ, and he founded a venture capital-backed medical software company MedAptus, Inc. where he was Chief Medical officer and capital fundraiser.During Baldo's tenure at Genentech, he oversaw the successful medical launch of a number of new medicines, including Hemlibra , a novel treatment for hemophilia A, and Ocrevus , the first B-cell therapy specifically indicated for multiple sclerosis.Before joining Adaptive, Baldo served in various roles of ascending responsibility with the Roche Group and its affiliates from February 2010 to April 2019, including most recently as senior vice president and head of US medical affairs of Genentech.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
In the wake of an office raid by the FBI last week, San Francisco microbiome firm uBiome has named its general counsel John Rakow as interim chief executive and placed its cofounders and co-CEOs on administrative leave. —BostonGene, which has developed patient analysis software to help clinicians make treatment decisions, raised $50 million in Series A funding. —Vividion Therapeutics of San Diego closed $82 million in Series B funding to advance cancer and immunology programs to clinical trials.
Cancer care is an excellent demonstration of the potential benefit of clinical pathways to both patients and the healthcare system. Identify biomarkers that inform treatment decisions Detect the presence of disease Assess prognosis Evaluate depth of response to therapy Monitor disease burden over time NGS tests have already had an significant impact on patient care and demonstrated potential value to the healthcare system, when appropriately used.
- - US-based Adaptive Biotechnologies has appointed Lance Baldo, M.D., as chief medical officer, the company said. Baldo brings 20 years of experience in both technology and therapeutics, combined with expertise in organisational design and change, including his most recent role as senior vice president and head of US medical affairs at Genentech, Inc., a member of the Roche Group. Before becoming head of US medical affairs, he was franchise head for ophthalmology, overseeing the launch of two new indications for Lucentis.